Incyte Gains European Commission Approval for Povofortay
Incyte said the European Commission has approved Povofortay (povorcitinib) for adults with moderate to severe hidradenitis suppurativa, a chronic skin disease. The company described the clearance as making the drug the first once-daily oral treatment available in the EU for the condition.
Incyte framed the approval as a new growth opportunity, saying the decision is supported by strong clinical results for the therapy. Hidradenitis suppurativa has had limited oral treatment options in Europe, according to the company's announcement.
The approval adds a commercial product in Europe for a company that reported revenue of 5.14 billion USD and net income of 1.29 billion USD in fiscal 2025. Incyte's next earnings date is scheduled for Feb 9, 2027.
Important questions to consider
The European Commission approved Povofortay, also known as povorcitinib, for adults with moderate to severe hidradenitis suppurativa. Incyte said it is the first once-daily oral treatment approved in the EU for the condition.
The company called the clearance a new growth opportunity and said it is backed by strong clinical results. It also noted the drug is the first once-daily oral option for the disease in Europe.
Incyte reported revenue of 5.14 billion USD and net income of 1.29 billion USD in fiscal 2025. The company's next earnings report is expected on Feb 9, 2027.
Sources
- INCY Wins European Commission Nod For Skin Disease Drug
Zacks Investment Research
- Incyte says EU approves oral treatment for chronic skin disease
Reuters
- Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa
Business WirePress release